MEB and Swissmedic sign MoU to step up collaboration

17 September 2018
swissmedic_big

The Netherlands’ Medicines Evaluation Board (MEB) intends to intensify collaboration with its partner authority in Switzerland in the field of therapeutic product development and production.

On September 11, 2018, MEB chairman Ton de Boer and executive director Hugo Hurts signed a memorandum of understanding (MoU) with Swissmedic director Raimund Bruhin.

The MoU provides a formal basis for stepping up collaboration on bilateral initiatives and the exchange of data. The two authorities are also involved in global multilateral initiatives such as the International Coalition of Medicines Regulatory Authorities (ICMRA) and the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Closer cooperation between the MEB and Swissmedic therefore benefits both parties and will help them to accomplish their mission efficiently.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical